SCHEMBL6667751

SCHEMBL6667751

O=c1cc(O)[nH]c2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.60
CYP1A2 P05177 2/20 0.60
KDM4E B2RXH2 7/20 0.59
HPGD P15428 6/20 0.59
ALDH1A1 P00352 4/20 0.59
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
HSD17B10 Q99714 2/20 0.59
GLA P06280 2/20 0.59
GRIN2D O15399 1/20 0.59
GRIN3B O60391 1/20 0.59
MAPK1 P28482 1/20 0.59
CYP2C19 P33261 1/20 0.59
AHR P35869 1/20 0.59
CHRNA7 P36544 1/20 0.59
GRIN1 Q05586 1/20 0.59
GRIN2A Q12879 1/20 0.59
GRIN2B Q13224 1/20 0.59
GRIN2C Q14957 1/20 0.59
GRIN3A Q8TCU5 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2639080 0.80 DAO (0.61) GAACYP1A2KDM4EHPGDALDH1A1
SCHEMBL9163258 0.75 CYP1A2 (0.60) GAACYP1A2KDM4EHPGDALDH1A1
SCHEMBL30199901 0.75 GAA (0.60) GAACYP1A2KDM4EHPGDALDH1A1
SCHEMBL10070259 0.75 CYP1A2 (0.60) GAACYP1A2KDM4EHPGDALDH1A1
SCHEMBL18995263 0.75 CYP1A2 (0.60) GAACYP1A2KDM4EHPGDALDH1A1
SCHEMBL7938807 0.75 CYP1A2 (0.60) GAACYP1A2KDM4EHPGDALDH1A1
SCHEMBL4741376 0.75 GAA (0.60) GAACYP1A2KDM4EHPGDALDH1A1
SCHEMBL7815453 0.75 CYP1A2 (0.60) GAACYP1A2KDM4EHPGDALDH1A1
SCHEMBL527043 0.75 CYP1A2 (1.00) GAACYP1A2KDM4EHPGDALDH1A1
Transtorine SCHEMBL5144405 0.75 KDM4E (1.00) GAACYP1A2KDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0062001-B1 ACYL QUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE CIBA-GEIGY AG (CH) 1987-05-27 EP claimed
EP-3950687-B1 INDUSTRIAL METHOD FOR SYNTHESISING IMIQUIMOD FROM QUINOLINE-2,4-DIOL APPLICABLE TO THE PHARMACEUTICAL USE THEREOF GENERYZE (FR) 2026-01-28 EP disclosed
EP-3950687-A1 INDUSTRIAL METHOD FOR SYNTHESISING IMIQUIMOD FROM QUINOLINE-2,4-DIOL APPLICABLE TO THE PHARMACEUTICAL USE THEREOF PHV Pharma (FR) 2022-02-09 EP disclosed
EP-2997382-B1 ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF UNIV NOTTINGHAM (GB) 2018-07-11 EP disclosed
US-20160131648-A1 ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF THE UNIVERSITY OF NOTTINGHAM (GB) 2016-05-12 US disclosed
US-20160131648-A1 ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF THE UNIVERSITY OF NOTTINGHAM (GB) 2016-05-12 US disclosed
WO-2014184535-A1 ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF THE UNIVERSITY OF NOTTINGHAM (GB) 2014-11-20 WO disclosed
EP-1450802-A2 METHODS FOR THE PREVENTION OR TREATMENT OF BACTERIAL AND FUNGAL INFECTIONS THE GENERAL HOSPITAL CORPORATION (US) 2004-09-01 EP disclosed
WO-2003037259-A2 METHODS FOR THE PREVENTION OR TREATMENT OF BACTERIAL AND FUNGAL INFECTIONS THE GENERAL HOSPITAL CORPORATION (US) 2003-05-08 WO disclosed
WO-2000074667-A2 COMPOSITIONS ACTIVE IN TELOMERE DAMAGE COMPRISING A TAXANE AND TELOMERASE INHIBITOR AU JESSIE L S (US) 2000-12-14 WO disclosed
US-5312922-A Quinoline derivatives with hydroxy, trifluoromethyl, carboxy and/or bromo substituents NORDION INTERNATIONAL INC. (CA) 1994-05-17 US disclosed
US-4476132-A Acylquinolinone derivatives, and antiallergic preparations and methods of inhibiting allergic reactions using them CIBA-GEIGY CORPORATION (US) 1984-10-09 US disclosed
EP-0062001-A2 Acyl quinolinone derivatives, processes for their preparation, pharmaceutical compositions containing them and their use CIBA-GEIGY AG (CH) 1982-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160131648-A1 ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF NQO2, QARS1, CD14 GAA 1539/4885CYP1A2 353/4885KDM4E 4049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.